C9orf142 transcriptionally activates MTBP to drive progression and resistance to CDK4/6 inhibitor in triple‐negative breast cancer

BACKGROUND: Triple‐negative breast cancer (TNBC) presents the most challenging subtype of all breast cancers because of its aggressive clinical phenotypes and absence of viable therapy targets. In order to identify effective molecular targets for treating patients with TNBC, we conducted an integrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Li, Deng, Ling, Zhang, Yin‐Ling, Yang, Shao‐Ying, Andriani, Lisa, Hu, Shu‐Yuan, Zhang, Fang‐Lin, Shao, Zhi‐Min, Li, Da‐Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679971/
https://www.ncbi.nlm.nih.gov/pubmed/38009308
http://dx.doi.org/10.1002/ctm2.1480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679971/
https://www.ncbi.nlm.nih.gov/pubmed/38009308
http://dx.doi.org/10.1002/ctm2.1480

Ejemplares similares